Payment overview · 2025
General Payments
$3,324.65
146 reported records · 34 companies
Healthcare provider profile · identity verified
Marc N Raad, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · WOLCOTT, CT · NPI 1316085665
Verified facts
What the public records show
CMS Open Payments records show Marc N Raad, M.D. received $3,324.65 in general payments during 2025 across 146 reported records.
AstraZeneca Pharmaceuticals LP accounted for 11.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 49 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Creon, Farxiga, Gemtesa, Ingrezza, Invega Sustenna, Jardiance, Kerendia, Linzess, Lokelma, Mounjaro, Nuplazid, Otezla, Ozempic, Qulipta, Rexulti, Rybelsus, Synthroid, Trintellix, Vraylar, Yupelri, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Vraylar by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Nuplazid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Otezla by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 448 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 295 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 572 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 2592 claims for Eliquis by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SPRYCEL as an associated drug or biological on 32 records involving 32 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Sprycel by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Invega Sustenna by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 740 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 572 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 258 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Rexulti by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Ingrezza by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 196 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 2592 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Lantus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported APTIOM as an associated drug or biological on 11 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Aptiom by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 1080 claims for Gemtesa by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Trintellix by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Austedo by this doctor in 2024.
Viatris Specialty LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported YUPELRI as an associated drug or biological on 26927 records involving 11152 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Yupelri by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $380.26 | 11.4% | 10 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $377.71 | 11.4% | 14 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $297.14 | 8.9% | 14 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $242.71 | 7.3% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $206.58 | 6.2% | 11 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $192.60 | 5.8% | 8 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $167.46 | 5.0% | 7 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $147.17 | 4.4% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $137.64 | 4.1% | 12 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $131.00 | 3.9% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $104.18 | 3.1% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $90.40 | 2.7% | 5 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $84.36 | 2.5% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $71.60 | 2.1% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $58.51 | 1.8% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $55.63 | 1.7% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $53.00 | 1.6% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $51.19 | 1.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $49.79 | 1.5% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $45.82 | 1.4% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $38.59 | 1.2% | 2 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $34.16 | 1.0% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $32.91 | 1.0% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $30.94 | 0.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $30.29 | 0.9% | 1 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$29.08 | 0.9% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $26.84 | 0.8% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $26.02 | 0.8% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $24.96 | 0.8% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $24.51 | 0.7% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.28 | 0.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.65 | 0.7% | 1 | 2025 |
| Luye Pharma (USA) Ltd. | Unresolved — no canonical attribution shown | $18.89 | 0.6% | 1 | 2025 |
| EVOKE PHARMA, INC. | Unresolved — no canonical attribution shown | $18.78 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,324.65 | 146 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $377.71 | 14 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $297.14 | 14 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $250.92 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $248.15 | 11 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $224.10 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $222.89 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $206.58 | 11 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $167.46 | 7 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $161.80 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $149.27 | 9 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $142.12 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $129.38 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $126.68 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $125.56 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $125.56 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $91.83 | 7 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $90.40 | 5 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $84.36 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $77.96 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $71.60 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $58.51 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $55.63 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $55.63 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $53.00 | 2 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $51.19 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $49.79 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $45.82 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $45.82 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $39.72 | 2 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $34.16 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $32.91 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $30.94 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $26.84 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $26.22 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $26.02 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $24.96 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $24.51 | 1 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $23.11 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $22.28 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $22.01 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.65 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.65 | 1 | 2025 |
Source payment records
|
|||||
| MYFEMBREE Normalized: myfembree |
Drug | Sumitomo Pharma America, Inc. | $20.49 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $19.73 | 2 | 2025 |
Source payment records
|
|||||
| ERZOFRI EXTENDED-RELEASE Normalized: erzofri extended release |
Drug | Luye Pharma (USA) Ltd. | $18.89 | 1 | 2025 |
Source payment records
|
|||||
| GIMOTI Normalized: gimoti |
Drug | EVOKE PHARMA, INC. | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $4.07 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $4.07 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 15 | exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 295 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 1080 | exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 104 | exact normalized | Medicare Part D |
| INVEGA SUSTENNA invega sustenna |
2025 | Invega Sustenna | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 572 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 156 | exact normalized | Medicare Part D |
| LOKELMA lokelma |
2025 | Lokelma | 2024 | 58 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 56 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 164 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 69 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 91 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 96 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| YUPELRI yupelri |
2025 | Yupelri | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
156 | 43 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
96 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
19 | 13 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
448 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
68 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
295 | 29 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
58 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
70 | 21 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
572 | 65 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
2592 | 165 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | SPRYCEL open payments reported associated product |
CMS Open Payments — General Payments 32 supporting records · 32 recipient NPIs · example record 1184390211 |
Sprycel · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
740 | 51 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
572 | 65 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
258 | 39 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
69 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
104 | 12 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
196 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
164 | 36 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
132 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
69 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
2592 | 165 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
140 | 27 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | APTIOM open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 11 recipient NPIs · example record 1176658319 |
Aptiom · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
1080 | 65 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
91 | 11 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Viatris Specialty LLC Exact reporting entity; no affiliate inference |
2025 | YUPELRI open payments reported associated product |
CMS Open Payments — General Payments 26927 supporting records · 11152 recipient NPIs · example record 1238463489 |
Yupelri · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 5964 | 429 |
| Trazodone Hcl | Trazodone Hcl | 5513 | 370 |
| Gabapentin | Gabapentin | 4076 | 252 |
| Amlodipine Besylate | Amlodipine Besylate | 3859 | 296 |
| Levothyroxine Sodium | Levothyroxine Sodium | 3712 | 255 |
| Pantoprazole Sodium | Pantoprazole Sodium | 3119 | 295 |
| Furosemide | Furosemide | 3026 | 240 |
| Mirtazapine | Mirtazapine | 2885 | 227 |
| Escitalopram Oxalate | Escitalopram Oxalate | 2723 | 163 |
| Metoprolol Succinate | Metoprolol Succinate | 2673 | 182 |
| Eliquis | Apixaban | 2592 | 165 |
| Lisinopril | Lisinopril | 2489 | 176 |
| Tamsulosin Hcl | Tamsulosin Hcl | 2439 | 185 |
| Metformin Hcl | Metformin Hcl | 2296 | 191 |
| Donepezil Hcl | Donepezil Hcl | 2111 | 115 |
| Sertraline Hcl | Sertraline Hcl | 2025 | 128 |
| Metoprolol Tartrate | Metoprolol Tartrate | 1948 | 150 |
| Quetiapine Fumarate | Quetiapine Fumarate | 1875 | 100 |
| Divalproex Sodium | Divalproex Sodium | 1713 | 96 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1272 | 156 |
| Omeprazole | Omeprazole | 1207 | 100 |
| Losartan Potassium | Losartan Potassium | 1170 | 106 |
| Potassium Chloride | Potassium Chloride | 1143 | 115 |
| Gemtesa | Vibegron | 1080 | 65 |
| Risperidone | Risperidone | 1038 | 55 |
| Clopidogrel | Clopidogrel Bisulfate | 1017 | 87 |
| Olanzapine | Olanzapine | 996 | 78 |
| Duloxetine Hcl | Duloxetine Hcl | 980 | 74 |
| Levetiracetam | Levetiracetam | 954 | 66 |
| Montelukast Sodium | Montelukast Sodium | 931 | 77 |
| Memantine Hcl | Memantine Hcl | 920 | 61 |
| Carvedilol | Carvedilol | 886 | 72 |
| Simvastatin | Simvastatin | 873 | 72 |
| Buspirone Hcl | Buspirone Hcl | 805 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 743 | 70 |
| Xarelto | Rivaroxaban | 740 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 715 | 48 |
| Finasteride | Finasteride | 667 | 45 |
| Baclofen | Baclofen | 626 | 42 |
| Aripiprazole | Aripiprazole | 620 | 38 |
| Famotidine | Famotidine | 598 | 65 |
| Spironolactone | Spironolactone | 573 | 37 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 572 | 30 |
| Jardiance | Empagliflozin | 572 | 65 |
| Fluoxetine Hcl | Fluoxetine Hcl | 559 | 37 |
| Januvia | Sitagliptin Phosphate | 531 | 40 |
| Paroxetine Hcl | Paroxetine Hcl | 518 | 39 |
| Prednisone | Prednisone | 483 | 79 |
| Allopurinol | Allopurinol | 479 | 56 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 468 | 29 |
| Myrbetriq | Mirabegron | 448 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 430 | 39 |
| Divalproex Sodium Er | Divalproex Sodium | 425 | 22 |
| Alprazolam | Alprazolam | 407 | 63 |
| Atenolol | Atenolol | 395 | 28 |
| Benztropine Mesylate | Benztropine Mesylate | 383 | 38 |
| Ropinirole Hcl | Ropinirole Hcl | 371 | 27 |
| Tradjenta | Linagliptin | 362 | 27 |
| Topiramate | Topiramate | 361 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 360 | 21 |
| Torsemide | Torsemide | 356 | 29 |
| Meloxicam | Meloxicam | 355 | 69 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 350 | 49 |
| Tizanidine Hcl | Tizanidine Hcl | 348 | 26 |
| Propranolol Hcl | Propranolol Hcl | 328 | 24 |
| Midodrine Hcl | Midodrine Hcl | 321 | 40 |
| Ezetimibe | Ezetimibe | 314 | 21 |
| Amiodarone Hcl | Amiodarone Hcl | 302 | 22 |
| Lactulose | Lactulose | 301 | 63 |
| Farxiga | Dapagliflozin Propanediol | 295 | 29 |
| Oxcarbazepine | Oxcarbazepine | 292 | 14 |
| Bupropion Xl | Bupropion Hcl | 272 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 261 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 260 | 105 |
| Lubiprostone | Lubiprostone | 259 | 13 |
| Trulicity | Dulaglutide | 258 | 39 |
| Lorazepam | Lorazepam | 256 | 43 |
| Ondansetron Hcl | Ondansetron Hcl | 249 | 89 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 235 | 19 |
| Carbamazepine | Carbamazepine | 234 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 234 | 79 |
| Hydralazine Hcl | Hydralazine Hcl | 229 | 30 |
| Metformin Hcl Er | Metformin Hcl | 226 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 226 | 22 |
| Tramadol Hcl | Tramadol Hcl | 225 | 59 |
| Sucralfate | Sucralfate | 219 | 21 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 212 | 75 |
| Entresto | Sacubitril/Valsartan | 196 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 194 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 191 | 68 |
| Doxazosin Mesylate | Doxazosin Mesylate | 188 | 14 |
| Methocarbamol | Methocarbamol | 181 | 31 |
| Folic Acid | Folic Acid | 177 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 176 | 31 |
| Glipizide | Glipizide | 176 | 17 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 174 | 24 |
| Fenofibrate | Fenofibrate Nanocrystallized | 173 | 17 |
| Bumetanide | Bumetanide | 170 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 166 | 20 |
| Ozempic | Semaglutide | 164 | 36 |
| Mupirocin | Mupirocin | 163 | 62 |
| Digoxin | Digoxin | 160 | 12 |
| Clozapine | Clozapine | 159 | 12 |
| Gemfibrozil | Gemfibrozil | 157 | 12 |
| Linzess | Linaclotide | 156 | 43 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 154 | 88 |
| Cephalexin | Cephalexin | 154 | 53 |
| Primidone | Primidone | 153 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 151 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 149 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 148 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 146 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 141 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 141 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 140 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 139 | 28 |
| Haloperidol | Haloperidol | 137 | suppressed |
| Lamotrigine | Lamotrigine | 136 | 17 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 132 | suppressed |
| Acyclovir | Acyclovir | 129 | 14 |
| Amantadine | Amantadine Hcl | 126 | 14 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 126 | 85 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 123 | 33 |
| Amitriptyline Hcl | Amitriptyline Hcl | 122 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 120 | suppressed |
| Nifedipine Er | Nifedipine | 120 | suppressed |
| Valsartan | Valsartan | 120 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 119 | 25 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 119 | 16 |
| Clonazepam | Clonazepam | 118 | 19 |
| Memantine Hcl Er | Memantine Hcl | 118 | 12 |
| Perphenazine | Perphenazine | 118 | suppressed |
| Latanoprost | Latanoprost | 117 | 30 |
| Rivastigmine | Rivastigmine Tartrate | 116 | suppressed |
| Silodosin | Silodosin | 116 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 114 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 113 | 19 |
| Enalapril Maleate | Enalapril Maleate | 112 | suppressed |
| Ketoconazole | Ketoconazole | 112 | 30 |
| Ranolazine Er | Ranolazine | 107 | suppressed |
| Ibuprofen | Ibuprofen | 106 | 31 |
| Nystatin | Nystatin | 106 | 46 |
| Ingrezza | Valbenazine Tosylate | 104 | 12 |
| Pregabalin | Pregabalin | 100 | 21 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 99 | 18 |
| Sevelamer Carbonate | Sevelamer Carbonate | 99 | 12 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 96 | suppressed |
| Vraylar | Cariprazine Hcl | 96 | suppressed |
| Azithromycin | Azithromycin | 95 | 70 |
| Diltiazem 24hr Er | Diltiazem Hcl | 95 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 94 | 12 |
| Flecainide Acetate | Flecainide Acetate | 93 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 93 | 11 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 92 | 20 |
| Carbamazepine Er | Carbamazepine | 91 | suppressed |
| Enulose | Lactulose | 91 | 17 |
| Glipizide Er | Glipizide | 91 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 91 | 11 |
| Alendronate Sodium | Alendronate Sodium | 90 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 90 | 11 |
| Incruse Ellipta | Umeclidinium Bromide | 89 | 14 |
| Humalog Kwikpen U-100 | Insulin Lispro | 88 | 20 |
| Chlorthalidone | Chlorthalidone | 85 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 84 | 39 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 84 | 33 |
| Fenofibrate | Fenofibrate | 84 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 84 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 81 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 80 | suppressed |
| Naproxen | Naproxen | 80 | 14 |
| Nyamyc | Nystatin | 80 | 30 |
| Fenofibrate | Fenofibrate,micronized | 79 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 79 | 22 |
| Silver Sulfadiazine | Silver Sulfadiazine | 79 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 79 | 43 |
| Lovastatin | Lovastatin | 77 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 77 | 17 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 76 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 76 | 24 |
| Spiriva Handihaler | Tiotropium Bromide | 76 | 11 |
| Fluphenazine Hcl | Fluphenazine Hcl | 75 | suppressed |
| Methylprednisolone | Methylprednisolone | 74 | 50 |
| Xifaxan | Rifaximin | 71 | suppressed |
| Alogliptin | Alogliptin Benzoate | 70 | suppressed |
| Glimepiride | Glimepiride | 70 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 70 | 21 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 69 | 25 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 69 | 57 |
| Rexulti | Brexpiprazole | 69 | suppressed |
| Brilinta | Ticagrelor | 68 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 68 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 68 | 27 |
| Ondansetron Odt | Ondansetron | 68 | 33 |
| Lidocaine | Lidocaine | 67 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 66 | 33 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 65 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 63 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 62 | suppressed |
| Estradiol | Estradiol | 62 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 60 | 22 |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 60 | 27 |
| Probenecid | Probenecid | 60 | suppressed |
| Levetiracetam Er | Levetiracetam | 59 | suppressed |
| Mirabegron Er | Mirabegron | 59 | 12 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 58 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 58 | 16 |
| Mresvia | Rsv Vaccine, Pref, Mrna/Pf | 58 | 58 |
| Novolog Flexpen | Insulin Aspart | 57 | 14 |
| Propranolol Hcl Er | Propranolol Hcl | 57 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 57 | 30 |
| Ventolin Hfa | Albuterol Sulfate | 57 | 29 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 56 | 25 |
| Labetalol Hcl | Labetalol Hcl | 56 | suppressed |
| Mesalamine | Mesalamine | 56 | suppressed |
| Methimazole | Methimazole | 56 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 56 | suppressed |
| Budesonide | Budesonide | 55 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 55 | suppressed |
| Vascepa | Icosapent Ethyl | 55 | suppressed |
| Acetazolamide Er | Acetazolamide | 54 | suppressed |
| Leflunomide | Leflunomide | 53 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 52 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 38 |
| Gentamicin Sulfate | Gentamicin Sulfate | 50 | 14 |
| Kerendia | Finerenone | 50 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 50 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 50 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 50 | suppressed |
| Cilostazol | Cilostazol | 49 | suppressed |
| Erythromycin | Erythromycin Base | 49 | 20 |
| Insulin Lispro | Insulin Lispro | 49 | 16 |
| Lithium Carbonate | Lithium Carbonate | 49 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 49 | suppressed |
| Austedo | Deutetrabenazine | 47 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 47 | 28 |
| Rytary | Carbidopa/Levodopa | 47 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 46 | 17 |
| Synthroid | Levothyroxine Sodium | 45 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 45 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 44 | 18 |
| Levofloxacin | Levofloxacin | 44 | 24 |
| Creon | Lipase/Protease/Amylase | 43 | suppressed |
| Metronidazole | Metronidazole | 43 | 17 |
| Atropine Sulfate | Atropine Sulfate | 41 | 15 |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 41 | 28 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 41 | suppressed |
| Lacosamide | Lacosamide | 41 | suppressed |
| Restasis | Cyclosporine | 41 | suppressed |
| Calcitriol | Calcitriol | 40 | suppressed |
| Celecoxib | Celecoxib | 40 | 13 |
| Risperdal Consta | Risperidone Microspheres | 40 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 39 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 39 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 39 | 11 |
| Mounjaro | Tirzepatide | 39 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 39 | 15 |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 38 | suppressed |
| Eszopiclone | Eszopiclone | 38 | 13 |
| Prednisolone Acetate | Prednisolone Acetate | 38 | 17 |
| Cefdinir | Cefdinir | 37 | suppressed |
| Nateglinide | Nateglinide | 37 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | suppressed |
| Timolol Maleate | Timolol Maleate | 37 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 37 | suppressed |
| Trospium Chloride | Trospium Chloride | 36 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 35 | 17 |
| Nitroglycerin | Nitroglycerin | 35 | 28 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 35 | suppressed |
| Procrit | Epoetin Alfa | 35 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 35 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 35 | suppressed |
| Amoxicillin | Amoxicillin | 34 | 26 |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 34 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | 11 |
| Brinzolamide | Brinzolamide | 32 | suppressed |
| Phenytoin | Phenytoin | 32 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 31 | 15 |
| Diazepam | Diazepam | 31 | suppressed |
| Fluconazole | Fluconazole | 31 | 18 |
| Prazosin Hcl | Prazosin Hcl | 31 | suppressed |
| Trifluoperazine Hcl | Trifluoperazine Hcl | 31 | suppressed |
| Insulin Aspart | Insulin Aspart | 30 | suppressed |
| Novolog | Insulin Aspart | 30 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 29 | suppressed |
| Colchicine | Colchicine | 29 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 29 | suppressed |
| Levemir | Insulin Detemir | 29 | suppressed |
| Atovaquone | Atovaquone | 28 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 28 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 28 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 28 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 27 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 27 | suppressed |
| Pentoxifylline | Pentoxifylline | 27 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 27 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Victoza 3-Pak | Liraglutide | 26 | suppressed |
| Anastrozole | Anastrozole | 25 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 25 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 25 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 25 | suppressed |
| Multaq | Dronedarone Hcl | 25 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 25 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 24 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Paliperidone Er | Paliperidone | 23 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 22 | 11 |
| Humalog | Insulin Lispro | 22 | 11 |
| Lidocaine Hcl | Lidocaine Hcl | 22 | 18 |
| Ofloxacin | Ofloxacin | 22 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Yupelri | Revefenacin | 22 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 21 | 20 |
| Cyclosporine | Cyclosporine | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Formoterol Fumarate | Formoterol Fumarate | 21 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 21 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 21 | 20 |
| Rabeprazole Sodium | Rabeprazole Sodium | 21 | suppressed |
| Nystop | Nystatin | 20 | suppressed |
| Olanzapine Odt | Olanzapine | 20 | suppressed |
| Rocklatan | Netarsudil Mesylat/Latanoprost | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Prolia | Denosumab | 19 | 13 |
| Acetic Acid | Acetic Acid | 18 | suppressed |
| Cabergoline | Cabergoline | 18 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 18 | suppressed |
| Metolazone | Metolazone | 18 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 18 | 18 |
| Sodium Chloride | Sodium Chloride 0.45 % | 18 | suppressed |
| Ursodiol | Ursodiol | 18 | suppressed |
| Auryxia | Ferric Citrate | 17 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 17 | suppressed |
| Otezla | Apremilast | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Verapamil Sr | Verapamil Hcl | 17 | suppressed |
| Ceftriaxone | Ceftriaxone In Is-Osm Dextrose | 16 | suppressed |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Dexamethasone | Dexamethasone | 16 | 12 |
| Fluphenazine Decanoate | Fluphenazine Decanoate | 16 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 16 | suppressed |
| Movantik | Naloxegol Oxalate | 16 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 16 | 11 |
| Sumatriptan Succ-Naproxen Sod | Sumatriptan Succ/Naproxen Sod | 16 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 16 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 15 | 15 |
| Advair Diskus | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 15 | suppressed |
| Entacapone | Entacapone | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 15 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 14 | suppressed |
| Novolin R | Insulin Regular, Human | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Scopolamine | Scopolamine | 14 | suppressed |
| Travoprost | Travoprost | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Admelog | Insulin Lispro | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 13 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Dextrose In Water | Dextrose 5 % In Water | 13 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Levocarnitine | Levocarnitine | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Acitretin | Acitretin | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 12 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Hydroxyurea | Hydroxyurea | 12 | suppressed |
| Insulin Aspart Prot Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 12 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 12 | suppressed |
| Mesalamine Er | Mesalamine | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 12 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Bimatoprost | Bimatoprost | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Dextrose 5%-0.9% Nacl | Dextrose 5 % And 0.9 % Nacl | 11 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 11 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 11 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 11 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Motegrity | Prucalopride Succinate | 11 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Qulipta | Atogepant | 11 | suppressed |
| Renacidin | Citric Ac/Gluconolact/Mag Carb | 11 | suppressed |
| Sprycel | Dasatinib | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
| Valproic Acid | Valproic Acid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,324.65 · 146 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AFREZZA, AIRSUPRA, AUSTEDO XR, Auvelity, BREZTRI, CAPLYTA, CAPVAXIVE, COBENFY, CREON, Cologuard Collection Kit, ERZOFRI EXTENDED-RELEASE, FANAPT, FARXIGA, GARDASIL 9, GEMTESA, GIMOTI, HETLIOZ, IBSRELA, INGREZZA, INVEGA SUSTENNA, JARDIANCE, Kerendia, LEQVIO, LINZESS, LOKELMA, MOUNJARO, MYFEMBREE, NUPLAZID, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, SPRAVATO, SYNTHROID, TRINTELLIX, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, WATCHMAN FLX, YUPELRI, ZENPEP, ZEPBOUND | 40 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error